Anti‐nuclear autoantibodies: clinical utility for diagnosis, prognosis, monitoring, and planning of treatment strategy in systemic immunoinflammatory diseases

References

• Holborow E. J., Wyer D. M., Johanson G. D. A serum factor in lupus erythematosus with affinity for tissue nuclei. Br Med J 1957; ii: 732–8
   Google Scholar
• Friou G. J., Finch S. C., Detre K. D. Interaction of nuclei and globulin from lupus erythematosus serum demonstrated with fluorescent antibody. J Immunol 1958; 80: 324–9
   PubMed Web of Science ®Google Scholar
• Tan E. M. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989; 44: 93–152
   PubMed Web of Science ®Google Scholar
• von Mühlen C. A., Tan E. M. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995; 24: 323–58
   PubMed Web of Science ®Google Scholar
• Marchalonis J. J., Kaveri S., Lacroix‐Desmazes S., Kazatchkine M. D. Natural recognition repertoire and the evolutionary emergence of the combinatorial immune system. FASEB J 2002; 16: 842–8
   PubMed Web of Science ®Google Scholar
• Bayry J., Misra N., Latry V., Prost F., Delignat S., Lacroix‐Desmazes S., et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Tranfus Clin Biol 2003; 10: 165–9
   PubMed Web of Science ®Google Scholar
• Tan E. M., Feltkamp T. E., Smolen J. S., Butcher B., Dawkins R., Fritzler M. J., et al. Range of antinuclear antibodies in healthy individuals. Arthritis Rheum 1997; 40: 1601–11
   PubMed Web of Science ®Google Scholar
• Hahn B. H. Antibodies to DNA. N Engl J Med 1998; 338: 1359–68
   PubMed Web of Science ®Google Scholar
• Haugbro K., Nossent J. C., Winkler T., Figenschau Y., Rekvik O. P. Anti‐dsDNA antibodies and disease classification in antinuclear antibody positive patients: the role of analytical diversity. Ann Rheum Dis 2004; 63: 386–94
   PubMed Web of Science ®Google Scholar
• Cervera R., Vinas O., Ramos Casals M., Font J., Garcia‐Carrasco M., Siso A., et al. Anti‐chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis 2003; 62: 431–4
   PubMed Web of Science ®Google Scholar
• Fritzler M. J. Autoantibodies in scleroderma. J Dermatol 1993; 20: 257–68
   PubMedGoogle Scholar
• Vlachoyannopoulos P. G., Drosos A. A., Wiik A., Moutsopoulos H. M. Patients with anticentromere antibodies: clinical features, diagnoses and evolution. Br J Rheumatol 1993; 32: 297–301
   PubMedGoogle Scholar
• Targoff I. N. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002; 28: 859–90
   PubMed Web of Science ®Google Scholar
• Kasukawa R. Preliminary criteria for classification of mixed connective tissue disease. Mixed connective tissue disease and antinuclear antibodies., R Kasukawa, G. G Sharp, editors. Excerpta Medica, Amsterdam 1987; 41–7
   Google Scholar
• Rasmussen E. K., Ullman S., Høier‐Madsen M., Sørensen S. F., Halberg P. Clinical implications of ribonucleoprotein antibody. Arch Dermatol 1987; 123: 601–5
   PubMedGoogle Scholar
• Swaak T., Smeenk R. Detection of anti‐dsDNA as a diagnostic tool: a prospective study in 441 non‐systemic lupus erythematosus patients with anti‐dsDNA antibody (anti‐dsDNA). Ann Rheum Dis 1985; 44: 245–51
   PubMed Web of Science ®Google Scholar
• Kallenberg C. G. M., Wouda A. A., Hoet M. H., van Venrooij W. J. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow‐up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988; 47: 634–41
   PubMed Web of Science ®Google Scholar
• Arbuckle M. R., McClain M. T., Rubertone M. V., Scofield R. H., Dennis G. J., James J. A., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526–33
   PubMed Web of Science ®Google Scholar
• LeRoy E. C., Black C. M., Fleischmejer R., Jablowska S., Krieg T., Medsger T. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202–5
   PubMed Web of Science ®Google Scholar
• Kuwana M., Kaburaki J., Okano Y., Tojo T., Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 37: 75–83
   PubMed Web of Science ®Google Scholar
• Jacobsen S., Ullman S., Shen G. Q., Wiik A., Halberg P. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001; 28: 2454–9
   PubMed Web of Science ®Google Scholar
• Kuwana M., Okano Y., Kaburaki J., Tojo T., Medsger T. A., Jr. Racial differences in the distribution of systemic sclerosis‐related serum antinuclear antibodies. Arthritis Rheum 1994; 37: 902–6
   PubMed Web of Science ®Google Scholar
• Permin H., Hørbov S., Wiik A., Knudsen J. V. Antinuclear antibodies in chronic juvenile arthritis. Acta Paediatr Scand 1978; 67: 181–5
   PubMed Web of Science ®Google Scholar
• Ravelli A., Felici E., Magni‐Manzoni S., Pistorio A., Novarini C., Bozzola E., et al. Patients with antinuclear antibody‐positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum 2005; 52: 826–32
   PubMed Web of Science ®Google Scholar
• Jonsson R., Gordon T. P., Konttinen Y. T. Recent advances in understanding molecular mechanisms in the pathogenesis and antibody profile of Sjögren's syndrome. Curr Rheumatol Rep 2003; 5: 311–16
   PubMedGoogle Scholar
• ter Borg E. J., Horst G., Hummel E. J., Limburg P. C., Kallenberg C. G. Measurement of increased anti‐double‐stranded DNA antibody levels as a predictor of disease exacerbations in lupus erythematosus. A long‐term, prospective study. Arthritis Rheum 1990; 33: 634–43
   PubMed Web of Science ®Google Scholar
• Spronk P. E., Limburg P. C., Kallenberg C. G. Serological markers of disease activity in systemic lupus erythematosus. Lupus 1995; 4: 86–94
   PubMed Web of Science ®Google Scholar
• Tan E. M., Smolen J. S., McDougal J. S., Butcher B. T., Conn D., Dawkins R., et al. A critical evaluation of enzyme immunoassays for detection of antinuclear antibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum 1999; 42: 455–64
   PubMed Web of Science ®Google Scholar
• Fritzler M. J., Wiik A., Tan E. M., Smolen J. S., McDougal J. S., Chan E. K., et al. A critical evaluation of enzyme immunoassays for detection of antinuclear antibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturer's laboratories. J Rheumatol 2003; 30: 2374–81
   PubMed Web of Science ®Google Scholar
• Bizzaro N., Wiik A. Appropriateness in anti‐nuclear antibody testing: from clinical request to strategic laboratory practice. Clin Exp Rheumatol 2004; 22: 349–55
   PubMed Web of Science ®Google Scholar
• Kavanaugh A., Tomar R., Reveille J., Solomon D. H., Homburger H. A. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. Arch Pathol Lab Med 2000; 124: 71–81
   PubMed Web of Science ®Google Scholar
• Humbel R. L. Detection of antinuclear antibodies by immunofluorescence. Manual of biological markers of disease., R. N Maini, W. J van Venrooij, editors. Kluwer, Dordrecht 1993; 1–16
   Google Scholar
• Wiik A., Gordon T. P., Kavanaugh A. F., Lahita R. G., Reeves W., van Venrooij W. J., et al. Cutting edge diagnostics in rheumatology: the role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology. Arthritis Care Res 2004; 51: 291–8
   Web of Science ®Google Scholar
• Wiik A. Testing for ANA and ANCA – diagnostic value and pitfalls. Rheumatology, 3rd edn., M. C Hochberg, A. J Silman, J. S Smolen, M. E Weinblatt, M. H Weisman, editors. Mosby, Edinburgh 2003; 215–26
   Google Scholar
• Dahle C., Skogh T., Åberg A. K., Jalal A., Olcén P. Methods of choice for diagnostic antinuclear antibody (ANA) screening. Benefit of adding antigen‐specific assays to immunofluorescence microscopy. J Autoimmun 2004; 22: 241–8
   PubMed Web of Science ®Google Scholar
• Sonesson S. E., Salomonson S., Jacobsson L. A., Bremme K., Wahren‐Herlenius M. Signs of first degree heart block occur in one‐third of fetuses of pregnant women with anti‐SSA/Ro‐52 antibodies. Arthritis Rheum 2004; 50: 1253–61
   PubMedGoogle Scholar
• Bayer P. M., Bauerfeind S., Bienvenu J., Fabien N., Frei P. C., Gilburg B., et al. Multicenter evaluation study on a new Hep2 ANA screening enzyme immune assay. J Autoimmun 1999; 13: 89–93
   PubMed Web of Science ®Google Scholar
• Fenger M., Wiik A., Høier‐Madsen M., Lykkegaard J. J., Rozenfeld T., Hansen M. S., et al. Detection of antinuclear antibodies by solid‐phase immunoassays and immunofluorescence analysis. Clin Chem 2004; 50: 2141–7
   PubMed Web of Science ®Google Scholar
• Fritzler M. J., Wiik A., Fritzler M. L., Barr S. G. The use and abuse of commercial kits used to detect autoantibodies. Arthritis Res Ther 2003; 5: 192–201
   PubMed Web of Science ®Google Scholar
• Tan E. M. Autoantibodies in pathology and cell biology. Cell 1991; 67: 841–2
   PubMed Web of Science ®Google Scholar
• Casciola‐Rosen L., Anhalt G., Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179: 1317–30
   PubMed Web of Science ®Google Scholar
• Utz P., Anderson P. Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens. Arthritis Rheum 1998; 41: 1152–60
   PubMed Web of Science ®Google Scholar
• Rovere P., Sabbadini M. G., Fazzini F., Bondanze A., Zimmermann V. S., Ruglari, et al. Remnants of suicidal cells fostering systemic autoaggression. Apoptosis in the origin and maintenance of autoimmunity. Arthritis Rheum 2000; 43: 1663–72
   PubMedGoogle Scholar
• Nagaraju K., Raben N., Loeffler L., Parker T., Rochon P. J., Lee E., et al. Conditional up‐regulation of MHC class I in skeletal muscle leads to self‐sustaining autoimmune myositis and myositis‐specific autoantibodies. Proc Natl Acad Sci USA 2000; 97: 9209–14
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y., Rauch J., Massicotte H., Datta S. K., Andre‐Schwartz J., Stollar B. D., et al. Polyspecificity of monoclonal lupus autoantibodies produced by human–human hybridomas. N Engl J Med 1983; 308: 414–20
   PubMed Web of Science ®Google Scholar
• Pizetsky D. S., Hoch S. O., Klatt C. L., O'Donnell M. A., Keene J. D. Specificity and idiotypic analysis of a monoclonal anti‐Sm antibody with anti‐DNA activity. J Immunol 1985; 135: 4080–5
   PubMed Web of Science ®Google Scholar
• Koren E., Koscec M., Wolfson‐Reichlin M., Ebling F. M., Tsao B., Hahn B., et al. Murine and human antibodies to native DNA that cross‐react with the A and D snRNP polypeptides cause direct injury of cultured kidney cells. J Immunol 1995; 154: 4857–64
   PubMed Web of Science ®Google Scholar
• Sharma A., Isenberg D. A., Diamond B. Crossreactivity of human anti‐dsDNA antibodies to phosphorylcholine: clues to their origin. J Autoimmun 2001; 16: 479–84
   PubMed Web of Science ®Google Scholar
• DeGiorgio L. A., Konstantinov K. N., Lee S. C., Hardin J. A., Volpe B. T., Diamond B. A subset of lupus anti‐DNA antibodies cross‐reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001; 7: 1189–93
   PubMed Web of Science ®Google Scholar
• Moscato S., Pratesi F., Bongiorni F., Scavuzzo M. C., Chimenti D., Bombardieri S., et al. Endothelial cell binding by lupus antibodies: functional properties and relationship with anti‐DNA activity. J Autoimmun 2002; 18: 231–8
   PubMed Web of Science ®Google Scholar
• Caponi L., Chimenti D., Pratesi F., Migliorini P. Anti‐ribosomal antibodies from lupus patients bind DNA. Clin Exp Immunol 2002; 130: 541–7
   PubMed Web of Science ®Google Scholar
• Deocharan B., Qing X., Lichauco J., Putterman C. Alpha‐actinin is a cross‐reactive renal target for pathogenic anti‐DNA antibodies. J Immunol 2002; 168: 3072–8
   PubMed Web of Science ®Google Scholar
• Watanabe A., Kodera M., Sugiura K., Usuda T., Tan E. M., Takasaki Y., et al. Anti‐DSF70 antibodies in 597 healthy hospital workers. Arthritis Rheum 2004; 50: 892–900
   PubMed Web of Science ®Google Scholar
• Ochs R. L., Muro Y., Si Y., Ge H., Chan E. K., Tan E. M. Autoantibodies to DSF 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol 2000; 105: 1211–20
   PubMed Web of Science ®Google Scholar
• Hochberg M. C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725
   PubMed Web of Science ®Google Scholar
• Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–7
   PubMed Web of Science ®Google Scholar
• Vitali C., Bombardieri S., Moutsopoulos H. M., Balestrieri G., Bencivelli W., Bernstein R. M., et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1992; 36: 340–8
   Google Scholar
• Wilson W. A., Gharavi A. E., Koike T., Lockshin M. D., Branch D. W., Piette J‐C., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309–11
   PubMed Web of Science ®Google Scholar
• van Boekel M. A., Vossenaar E. R., van den Hoogen F. H., van Venrooij W. J. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002; 4: 87–93
   PubMedGoogle Scholar
• Szer W., Sierakowska H., Szer I. S. Antinuclear antobody profile in juvenile rheumatoid arthritis. J Rheumatol 1991; 18: 401–8
   PubMedGoogle Scholar
• Wiik A. Clinical use of serological tests for ANCA: what do the studies say?. Rheum Dis Clin North Am 2001; 27: 799–813
   PubMed Web of Science ®Google Scholar
• Utz P. J., Gensler T. J., Anderson P. Death, autoantigen modifications, and tolerance. Arthritis Res 2000; 2: 101–14
   PubMedGoogle Scholar